• Glaukos Corporation (NASDAQ: GKOS) announced positive topline data for both Phase 3 trials of iDose TR. It achieved its pre-specified primary efficacy endpoints through 3 months and demonstrated excellent tolerability and a favorable safety profile through 12 months.

• The fast- and slow-release iDose TR arms achieved the primary efficacy endpoint of non-inferiority to the active comparator arm (topical timolol ophthalmic solution).

• Related: Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment.

• For the GC-010 trial, the intraocular pressure (IOP) reductions from baseline were 6.6-8.5 mmHg in the slow-release iDose TR arm versus 6.6-7.7 mmHg in the timolol control arm.

• For the GC-012 trial, IOP reductions were 6.7-8.4 mmHg in the slow-release iDose TR arm versus 6.8-7.2 mmHg in the timolol control arm.

• 93% of slow-release iDose TR subjects remained well-controlled on the same or fewer IOP-lowering topical medications at 12 months compared to screening after a single administration of iDose TR, versus 67% of timolol control subjects.

• Additionally, 81% of slow-release iDose TR subjects were completely free of IOP-lowering topical medications.

• iDose TR demonstrated a favorable safety profile.

• Glaukos plans to move forward with its plans for marketing application submission to the FDA for the slow-release iDose TR model, with an expected FDA review and decision completed by the end of 2023.

• Price Action: GKOS shares are up 16.80% at $56.16 on the last check Wednesday.

See more from Benzinga

• Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment

• Tesla Motors (TSLA) – If You Invested $100 When Elon Musk First Tweeted About Dogecoin, Here's How Much Y

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.